Compare Enovix Corporation (ENVX) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Humana Inc — how do they compare? Enovix Corporation trades at $2.53 (market cap $549.72M), while Humana Inc trades at $445 (market cap $46.49B). The key difference: Humana Inc is far larger — about 84.6× Enovix Corporation's market cap, and Humana Inc pays a 0.91% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Humana Inc for 53 Days on average.
| ENVX | HUM | |
|---|---|---|
Market Cap | $549.72M | $46.49B |
Volume | 6,635,687 | 2,567,704 |
Sector | Industrials | Health |
52-Week High | $13.19 | $409.85 |
52-Week Low | $2.50 | $163.67 |
Typical Hold Time | 11 Days | 53 Days |
Enterprise Value | $611.42M | $53.84B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.55, down 5.56% on the day, reflecting a bearish technical outlook with significant selling pressure indicated by moving averages and oscillators. Fundamentally, the company is in a high-growth, pre-profitability phase, with revenue growing to $36 million in 2026 but net losses widening to -$170 million. Recent news is dominated by a sudden CEO resignation in August 2026, though the company reaffirmed its strategy and operational guidance.
The investment case hinges on the company's advanced battery technology and expansion plans, particularly in the defense and drone sectors, against a backdrop of persistent cash burn and high execution risk. Analyst consensus remains bullish with a $10.75 price target, but the stock faces near-term volatility from leadership uncertainty and the challenging path to profitability.
Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.
The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
